Business
SciSparc Announces 1-for-21 Reverse Share Split
Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly heldTel Aviv, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it intends to effect a one-for-twenty one (1-for-21)
About this update from Scisparc Ltd.
[{"type":"image","alt":"SciSparc Ltd","displaySize":"","headline":null,"caption":"SciSparc Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":296,"height":296,"url":"https://media.zenfs.com/en/globenewswire.com/be600651bf31c0eac5b1f38ffceddbae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MrHl.FxBjx0vaFl08ACRrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/be600651bf31c0eac5b1f38ffceddbae","width":296,"height":296}},"lazy":false},{"type":"text","content":"Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held","length":155,"tagName":"p"},{"type":"text","content":"Tel Aviv, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it intends to effect a one-for-twenty one (1-for-21) reverse share split (the “Reverse Share Split”) of the Company’s issued and outstanding ordinary shares, no par value per share (the “Ordinary Shares”), effective at the market open on July 3, 2025. The Ordinary Shares will continue to trade on the Nasdaq Capital Market under the existing trading symbol “SPRC” and will begin trading on a split-adjusted basis at the market open on July 3, 2025. The new CUSIP number for the Ordinary Shares following the Reverse Share Split will be M82618121.","length":839,"tagName":"p"},{"type":"text","content":"The Reverse Share Split was approved by the Company’s shareholders at the Company’s Annual General Meeting of Shareholders held on October 23, 2024, to be effected at the board of directors’ discretion within the approved parameters.","length":233,"tagName":"p"},{"type":"text","content":"The Reverse Share Split will not result in an adjustment to the authorized share capital of the Company under the Company’s amended and restated articles of association, as currently in effect (the “Articles”), which, as of the date hereof, consists of 75,000,000 Ordinary Shares.","length":280,"tagName":"p"},{"type":"text","content":"The Reverse Share Split will affect all shareholders uniformly and will not alter any shareholder’s percentage of ownership...